Drug Interactions in Cardio-Oncology

A tétel rövid nézete
dc.contributor.advisorMegyeri, Attila
dc.contributor.advisordeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorHassan, Sara Khaled Abdelaal Hassan
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentSzentmiklósi, József
dc.contributor.opponentHalasi , Barbara
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Igazságügyi Orvostani Intézet
dc.date.accessioned2026-05-26T08:57:08Z
dc.date.available2026-05-26T08:57:08Z
dc.date.created2025-04-16
dc.description.abstractAccording to statistics from the Global Burden of Disease (GBD) compare platform, cardiovascular diseases (CVDs) and cancers were the leading causes of patient morbidity and mortality worldwide between 2016 and 2019, measured in Disability Adjusted Life Years (DALYs). Both of these conditions can co-exist in a single patient and are linked to risk factors, such as dyslipidemia and hypertension (HTN). The simultaneous affliction of patients with both conditions mandates the co-administration of cardiac and oncologic drugs, which in turn leads to drug-drug interactions (DDIs), either pharmacodynamic (PD) or pharmacokinetic (PK). These DDIs, as a side effect, promote the development of more risk factors within these patients. In this thesis, I establish and highlight a potential causative link between these DDIs and the increased DALYs associated with CVDs and cancer, demonstrating several examples of combinative regimens that induce specific risk factors, such as HTN. Based on the information reviewed in this paper, the high DALYs in cardio-oncology patients may be partly iatrogenic, caused by DDIs, and further research is mandated to explore better combinative regimens with fewer adverse effects.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent45
dc.identifier.urihttps://hdl.handle.net/2437/407391
dc.language.isoen
dc.rights.infoHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectDrug-drug interactions
dc.subjectCardio-oncology
dc.subjectPharmacokinetics
dc.subjectPharmacology
dc.subjectCancer
dc.subjectGBD compare
dc.subjectHypertension
dc.subjectDyslipidemia
dc.subjectVenous thromboembolism
dc.subject.dspaceMedicine
dc.titleDrug Interactions in Cardio-Oncology
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
SaraKhaled_FinalThesis_PDF.pdf
Méret:
1.63 MB
Formátum:
Adobe Portable Document Format
Leírás:
Megjelenítés
Engedélyek köteg
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
license.txt
Méret:
1.94 KB
Formátum:
Item-specific license agreed upon to submission
Leírás:
Letöltés
Gyűjtemények
Theses (Faculty of Medicine)